Nanomaterial-Based Sensors for Early Detection of Alzheimer's Disease Markers

Muhit Rana [1*], Hilal Ahmad Rather [2], Mohd Arif Dar [3]

Abstract

Alzheimer's, a widespread form of dementia, profoundly affects millions worldwide, necessitating early detection for improved intervention and symptom management. Current diagnostic challenges stem from the disease's late-stage symptomatic presentation. Here, we explore the potential of nanomaterial-based sensors, leveraging nanoparticles, nanowires, and quantum dots, to detect specific biomarkers associated with Alzheimer's disease. These sensors offer high sensitivity and selectivity, promising a breakthrough in early diagnosis. Early detection not only enhances patient outcomes but also aids in clinical trials, research, and future planning. Through an examination of the mechanisms, advancements, and applications of these innovative sensors, our review sheds light on their pivotal role in reshaping the landscape of early Alzheimer's disease diagnosis.

Significance | Early detection of Alzheimer's disease through nanomaterial-based sensors enhances intervention, research, and patient care, promising a transformative impact on healthcare.

*Correspondence. Muhit Rana, Giner Inc. 89 Rumford Ave, Newton, MA 02466, USA
E-mail: mrana@ginerinc.com

Editor Md Shamsuddin sultan Khan, And accepted by the Editorial Board Mar 11, 2023 (received for review Nov 09, 2023)

Keywords: Alzheimer's disease detection, Nanomaterial-based sensors, Early diagnosis, Biomarkers Innovation

Introduction

Alzheimer's disease, a progressive neurological disorder causing cognitive decline and memory loss, stands as the most prevalent form of dementia affecting millions worldwide. It's characterized by the accumulation of abnormal brain proteins, impacting nerve cells and cognitive function (Selkoe, D. J., & Hardy, J. 2016; Kashifa, 2023).

The significance of early detection in Alzheimer's disease cannot be overstated. Identifying the disease at its inception offers avenues for early intervention, improved management of symptoms, and enhanced quality of life for patients and their families (Perneczky R. 2019, Rakesh, G. eta l., 2017). Additionally, early diagnosis is pivotal for engaging in clinical trials, facilitating research into potential treatments, and better planning for the future (Arvanitakis, Z., & Bennett, D. A. 2019, Sukhawathanakul, P. et al., 2021)

However, the challenge lies in the disease's typical late-stage symptomatic presentation, making early detection a critical yet difficult endeavor (Prince, M. et al., 2015, Jack, C. R. 2020). Innovative technologies like nanomaterial-based sensors hold promise in identifying specific disease-associated biomarkers, potentially enabling early intervention and improved outcomes (Selkoe, D. J., & Hardy, J. 2016, Moya-Alvarado, G. et al., 2016). These sensors leverage the unique properties of nanomaterials, such as nanoparticles, nanowires, and quantum dots, to detect specific biomarkers associated with various diseases (Livingston, G. et al.,

Author Affiliation.
[1] Giner Inc. 89 Rumford Ave, Newton, MA 02466, USA
[2] Research and Development Division, A TO Z HERBALS, Industrial estate, Tulbal, Sopore, J&K-193201 India.
[3] Faculty of Allied Health Sciences, Chettinad Hospital, and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India

Please cite this article:
Muhit Rana, Hilal Ahmad Rather et al. (2024). Nanomaterial-Based Sensors for Early Detection of Alzheimer's Disease Markers, Biosensors and Nanotherpanostics, 2(1), 1-15, 7331

2020). Their role in early detection is pivotal, especially in diseases like Alzheimer's, where identifying specific biomarkers at the earliest stages is pivotal, especially in diseases like Alzheimer's, where identifying specific biomarkers at the earliest stages is challenging. Nanomaterial-based sensors offer high sensitivity, selectivity, and the ability to detect minuscule concentrations of biomarkers, promising a breakthrough in early diagnosis (Jack, C. R. et al., 2018, Sperling, R. A., et al., 2016).

In this review, we explore the innovative landscape of nanomaterial-based sensors and their pivotal role in the early detection of Alzheimer's disease. By examining their mechanisms, advancements, and potential applications, we aim to highlight their significance in reshaping the landscape of early disease diagnosis and, specifically, the quest for timely Alzheimer's detection.

2. Diagnosis and detection of Alzheimer's disease

Diagnosing and detecting Alzheimer's disease involves a multi-faceted approach that combines various clinical assessments, tests, and tools. Table 1 provides a comparative overview of parameters associated with clinical assessments, imaging techniques, laboratory tests, genetic testing, and neuropsychological tests used in Alzheimer's disease diagnosis.

3. Nanomaterials for Sensor Development

Nanomaterials have gained significant attention in sensor development due to their unique properties at the nanoscale. These materials exhibit enhanced sensitivity, improved surface-to-volume ratio, and unique electronic, optical, and catalytic properties. They play a crucial role in advancing sensor technologies for various applications, including healthcare, environmental monitoring, and industrial processes (Pomerantseva, E. et al, 2019).

3.1. Application of Nanomaterials in Sensor Fabrication for Alzheimer's Disease Detection.

The use of nanomaterials in sensor fabrication for Alzheimer's disease detection has shown promising results, especially enhanced sensitivity, specificity, and potential for early diagnosis. Several types of nanomaterials have been employed for this purpose, each contributing unique advantages to the development of advanced Alzheimer's disease sensors.

3.1.1. Nanoparticles:

3.1.1.1. Gold Nanoparticles:

Gold nanoparticles are widely used in biosensors due to their excellent biocompatibility and unique optical properties. Functionalizing these nanoparticles with specific ligands allows for the detection of Alzheimer's disease markers, such as beta-amyloid peptides, through changes in their optical response (Liu, D., 2011).

3.1.1.2. Magnetic Nanoparticles:

Iron oxide nanoparticles, for instance, possess magnetic properties that aid in the separation and detection of biomolecules associated with Alzheimer's disease. Magnetic nanoparticle-based sensors are useful for the sensitive and selective detection of biomarkers in complex biological samples (Zeng, J., 2018).

3.1.2. Carbon Nanotubes:

Single-walled carbon nanotubes (SWCNTs) or multi-walled carbon nanotubes (MWCNTs) are known for their high surface area and excellent electrical conductivity. Functionalized carbon nanotubes can be utilized in sensors to detect specific proteins or nucleic acids related to Alzheimer's disease, providing enhanced sensitivity (Oh, J., et al,. 2013).

3.1.3. Quantum Dots:

Quantum dots (QDs) are semiconductor nanocrystals with unique optical properties, including size-tunable emission. In Alzheimer's disease sensing, QDs can be engineered to bind selectively to target biomolecules. Changes in their fluorescence characteristics can then indicate the presence and concentration of Alzheimer's-related markers (Tang, M., et al., 2018)

3.1.4. Graphene-based Nanocomposites:

Graphene and its derivatives, such as graphene oxide, have been incorporated into nanocomposites for sensor development. These nanocomposites exhibit high surface area, excellent electrical conductivity, and can be functionalized for specific binding with Alzheimer's disease biomarkers, providing a platform for sensitive detection (Lee, J., 2016).

Table 2 Compiles key findings from recent research articles focusing on the application of nanomaterials in the fabrication of sensors for the detection of Alzheimer's disease markers. Nanomaterials offer unique properties that enhance sensor performance, providing advantages such as increased sensitivity, specificity, and the potential for early diagnosis.

3.2. Advantages in Sensing Alzheimer's Disease Markers.

The advantages of using nanomaterials in sensing Alzheimer's disease markers, including enhanced sensitivity, selective binding, real-time monitoring, miniaturization, and biocompatibility, highlight their potential to revolutionize diagnostic approaches in comparison to traditional sources (Patra, J. K., et al, 2018).

3.2.1. Enhanced Sensitivity:

Nanomaterials, characterized by their expansive surface area and distinctive properties, play a transformative role in enhancing the sensitivity of sensors for Alzheimer's disease detection (Bilal, M., et al, 2020). The advanced surface area of nanomaterials, including nanoparticles, nanowires, and nanotubes, facilitates intensified interactions with specific biomolecules related to Alzheimer's. This heightened sensitivity, driven by unique physical and chemical properties, results in an improved signal-to-noise ratio, enabling the precise detection of low concentrations of Alzheimer's biomarkers. Such enhanced sensitivity not only allows for early diagnosis of the disease, crucial for intervention at its nascent stages, but also facilitates real-time monitoring and the potential for personalized medicine approaches (Chen, R., & Riviere, J. E. 2017).

Additionally, the compatibility of many nanomaterials with biological systems ensures accurate detection in complex biological environments, marking a significant stride in the advancement of Alzheimer's disease diagnostics and research.

3.2.2. Selective Binding:

Selective binding, a key attribute conferred by the functionalization of nanomaterials, underscores a fundamental advantage in sensor development for Alzheimer's disease (Haes, A. J., 2005). The process involves tailoring the surface properties of nanomaterials to selectively interact with specific biomarkers associated with the disease (Mu, B., 2014). By introducing molecular recognition elements or ligands onto the nanomaterials, such as antibodies or aptamers targeting Alzheimer's-related proteins, the sensors gain a heightened specificity (Chen, L., 1999). This means that the nanomaterial-based sensors can discern and bind specifically to the intended biomolecules, reducing the likelihood of interference from other molecules present in complex biological samples. The ability to selectively target Alzheimer's biomarkers enhances the accuracy of the sensor, minimizing false positives and ensuring precise identification of relevant signals. This selectivity is particularly crucial in the intricate biochemical landscape of Alzheimer's disease, where distinguishing specific biomarkers is essential for accurate diagnosis and monitoring of disease progression (Mehrotra, P. 2016). Overall, the selective binding capability conferred by nanomaterial functionalization elevates the performance of sensors, contributing significantly to the reliability and precision of Alzheimer's disease diagnostics.

***3.2.3. Real-time Monitoring*:**

Real-time monitoring, facilitated by nanomaterial-based sensors, represents a groundbreaking advancement in the landscape of Alzheimer's disease diagnostics (Hameed, A., et al., 2023). The unique properties of nanomaterials, such as their high surface area and enhanced sensitivity, enable continuous and dynamic tracking of biomarkers associated with Alzheimer's disease. These sensors, designed to rapidly respond to molecular changes, offer the capability to detect fluctuations in real-time, providing a timely and comprehensive understanding of disease progression. This real-time monitoring is pivotal for early detection, allowing clinicians to identify subtle biochemical changes before clinical symptoms manifest (Pei, X. M, et al., 2023). Moreover, the continuous data streams generated by these sensors hold immense potential for informing personalized disease management strategies. By capturing real-time insights into the evolving biomolecular landscape of Alzheimer's, nanomaterial-based sensors offer a proactive approach to disease management, potentially enabling interventions tailored to the specific needs of individual patients and contributing to more effective therapeutic outcomes (Marx, U. et al., 2016).

3.2.4. Miniaturization:

Miniaturization, empowered by the use of nanomaterials in sensor design, marks a transformative shift in the landscape of Alzheimer's disease diagnostics. Nanomaterials, characterized by their nanoscale dimensions and unique properties, enable the creation of compact and highly efficient sensors (Zeng, S. et al., 2014). This miniaturization not only enhances the portability of sensors but also opens doors for their deployment in point-of-care settings. The reduced size allows for swift and on-site testing, bringing diagnostic capabilities closer to patients and potentially accelerating the speed of Alzheimer's disease diagnosis. Furthermore, the compatibility of nanomaterials with various substrates facilitates seamless integration into wearable or implantable devices. This integration enables continuous, real-time monitoring of Alzheimer's biomarkers, offering a proactive approach to disease management (Prosa, M. et al., 2020). Wearable and implantable nanomaterial-based sensors hold the promise of providing clinicians with continuous insights into disease dynamics, fostering personalized treatment strategies, and advancing towards a future of more accessible and patient-centric Alzheimer's diagnostics (Choi, C. et al., 2018).

***3.2.5. Biocompatibility*:**

Biocompatibility is a crucial aspect when it comes to using nanomaterials for Alzheimer's disease detection. Nanomaterials, due to their incredibly small size and unique properties, need to interact harmoniously with biological systems to ensure accurate and safe detection of disease markers (Nguyen, C. K. et al., 2017). Fortunately, many nanomaterials exhibit excellent biocompatibility, meaning they don't cause harm to living organisms. The nanomaterials are designed to be compatible with biological tissues and fluids, minimizing the risk of adverse reactions or toxicity. This is especially important when developing sensors that may be used in or on the human body.

Nanomaterials with high biocompatibility offer several advantages. They allow for the creation of sensors that can be safely introduced into the body for tasks like continuous monitoring of biomarkers. For instance, if a nanomaterial-based sensor is implanted for Alzheimer's disease detection, its biocompatibility ensures that it won't negatively impact the surrounding tissues (Wang, F. et al., 2010) (Figure 1).

4. Exploring Nanomaterial-Based Sensors for Disease Progression Monitoring and Treatment Response Assessment.

The sensing mechanisms employed by nanomaterial-based sensors are important in their ability to detect Alzheimer's disease biomarkers. These mechanisms determine how the sensors interact with specific molecules and generate signals for detection. Several sensing mechanisms are commonly utilized in nanomaterial-based sensors, each with its unique advantages.

4.1. Electrochemical Sensing.

In electrochemical sensing, nanomaterials such as carbon nanotubes or nanoparticles are often employed to facilitate electron transfer during the detection process (Ahammad, A. J. S. et al., 2009). When the target biomarker, associated with Alzheimer's disease, binds to the nanomaterial surface, it induces changes in the electrical conductivity or electrochemical signals, providing a measurable response (Zeng, S. et al., 2014). This mechanism is particularly effective in creating sensitive and rapid sensors for biomarker detection (Figure 2).

4.2. Optical Sensing.

Optical sensing involves the interaction between nanomaterials, such as gold nanoparticles or quantum dots, and light. When these nanomaterials come into contact with Alzheimer's biomarkers, they can be engineered to undergo changes in color, fluorescence, or absorbance. (West, J. L. et al., 2003). This interaction is depicted by visual changes in the diagram (Figure 3). The light source represents external light used in the process. The optical changes are then detected by the optical sensor, offering real-time monitoring capabilities. Below diagram illustrates how nanomaterials' unique response to light enables optical sensors to provide non-invasive and dynamic detection of Alzheimer's biomarkers.

4.3. Field-Effect Transistor (FET) Sensing

Field-Effect Transistor (FET) sensing stands at the forefront of advanced detection methodologies, particularly in the realm of nanomaterial-based sensors (Pachauri, V., & Ingebrandt, S. 2016). This innovative approach harnesses the unique electronic properties of nanomaterials, such as graphene, to amplify the detection of biomolecules. The FET structure serves as a sensitive platform, where interactions with Alzheimer's biomarkers induce measurable changes in electrical conductance. The FET sensing mechanism involves the strategic placement of nanomaterials on the transistor surface. Upon binding with Alzheimer's biomarkers, these nanomaterials influence the flow of electrical current through the transistor, leading to detectable alterations. The unparalleled sensitivity of FET sensors enables the detection of biomarkers at ultra-low concentrations, making them particularly valuable for early-stage diagnosis. In the diagram below, the FET structure, including the transistor components, is illustrated. The nanomaterial, represented on the transistor surface, interacts with Alzheimer's biomarkers. This interaction affects the electrical current passing through the transistor, leading to detectable changes. The diagram emphasizes the high sensitivity of FET sensors and their suitability for miniaturized, wearable, or implantable devices for dynamic Alzheimer's biomarker detection (Table 3, Figure 4).

5. Recent Advances in Nanomaterial-Based Sensors for Alzheimer's Detection.

Recent years have witnessed remarkable progress in the development of nanomaterial-based sensors for Alzheimer's detection, marking a transformative era in the field of neurodegenerative disease diagnostics (Scarpa, E. et al., 2023). Here we will provide an in-depth exploration of the latest breakthroughs and innovative approaches that have propelled nanomaterial sensors to the forefront of Alzheimer's research.

5.1. Diverse Nanomaterial Platforms.

Advancements extend across a spectrum of nanomaterials, encompassing nanoparticles, nanowires, quantum dots, and graphene. Also, the landscape of nanomaterials for Alzheimer's detection has undergone a transformative evolution, showcasing a diverse array of platforms that researchers have skillfully leveraged (Senapati, S. et al., 2023). This expansion spans several categories, each bringing distinct advantages to the development of sensors tailored for Alzheimer's diagnostics. The following nanomaterial platforms stand out for their unique properties and the novel sensing capabilities they impart:

5.1.1. Nanoparticles:

Nanoparticles offer a high surface-to-volume ratio, facilitating increased interaction with biomarkers. Their versatile surface can be engineered for specific binding, contributing to heightened sensitivity in detecting Alzheimer's markers.

5.1.2. Nanowires:

Nanowires exhibit exceptional electrical conductivity and can be employed to construct highly sensitive sensors. Their one-dimensional structure enhances the efficiency of charge transfer during biomarker interactions, contributing to improved sensor performance.

5.1.3. Quantum Dots :

Quantum dots possess unique optical properties, including tunable fluorescence. Researchers harness these characteristics to engineer sensors that exhibit changes in color, fluorescence, or absorbance upon interaction with Alzheimer's biomarkers, enhancing detection specificity.

***5.1.4. Graphene*:**

Graphene, with its exceptional electrical conductivity and mechanical strength, is a versatile nanomaterial. Its large surface area allows for increased biomarker binding sites, leading to sensors with heightened sensitivity and the potential for rapid, accurate detection.

5.2. Precision through Functionalization.

Functionalization with specific ligands or biomolecules enhances the sensor's ability to selectively bind to target biomarkers, contributing to improved diagnostic accuracy (Da Fonseca Soares Rodrigues, P. et al., 2023). The strategy of precision through functionalization stands as a pivotal approach in advancing the selectivity of nanomaterial-based sensors for Alzheimer's detection. By tailoring the surface properties of nanomaterials, researchers aim to enhance the specificity of these sensors. This involves the strategic attachment of specific ligands or biomolecules onto the nanomaterial surface. The outcome is a sensor with an augmented ability to selectively bind to predetermined target biomarkers associated with Alzheimer's disease (Hampel, H. et al., 2018). This fine-tuning of surface functionality plays a crucial role in elevating the diagnostic accuracy of the sensors, ensuring a more nuanced and reliable detection of Alzheimer's biomarkers.

5.3. Multi-Modal Sensing Strategies.

The emerging trend of multi-modal sensing strategies represents a significant leap forward in the development of nanomaterial-based sensors for Alzheimer's detection. This approach entails the integration of diverse nanomaterials and sensing mechanisms into a unified platform, giving rise to multi-modal sensors (Malini, S. et al., 2022). Unlike traditional single-modal sensors, these advanced sensors aim to capture a comprehensive profile of Alzheimer's biomarkers, recognizing the intricate and multifaceted nature of the disease (Chung, Y. 2022). The synergy between different nanomaterials and sensing mechanisms contributes to a more accurate and robust detection system, paving the way for novel diagnostic insights that go beyond the capabilities of individual sensing modalities.

5.4. Real-Time Monitoring Capabilities.

In the process of Alzheimer's detection, a notable breakthrough lies in the incorporation of real-time monitoring capabilities into nanomaterial-based sensors. Recent innovations have empowered these sensors to continuously track Alzheimer's biomarkers, providing instantaneous and dynamic insights into the fluctuating levels of relevant molecules (Murti, B. et al., 2021). This real-time monitoring capability holds significant implications for understanding the temporal aspects of Alzheimer's disease. Also, by offering a continuous stream of data, nanomaterial-based sensors with real-time monitoring capabilities contribute to a more detailed comprehension of disease progression. Researchers and clinicians can observe the dynamic changes in biomarker levels over time, allowing for a more accurate depiction of the disease's evolution. This real-time feedback is invaluable not only for understanding the natural course of Alzheimer's but also for evaluating the effectiveness of interventions and treatments (Rostamzadeh, A. 2022).

5.5. Miniaturization and Wearable Devices.

The paradigm shift towards miniaturization marks a significant stride in the evolution of nanomaterial-based sensors for Alzheimer's detection. This transformative trend has given rise to the development of wearable and implantable devices that leverage nanomaterials for continuous monitoring (Stavropoulos, T. G. et al., 2021). These compact sensors not only enhance portability but also introduce the potential for non-invasive, real-time tracking of Alzheimer's biomarkers (Hsu, C. L. et al., 2020). Moreover, miniaturization, coupled with the integration of nanomaterial sensors into everyday wearables, can give rise to a range of benefits. These devices can seamlessly accompany individuals in their daily lives, providing a continuous stream of data without disrupting routine activities. The compact size and unobtrusive nature of these sensors make them well-suited for long-term monitoring, offering a holistic view of biomarker fluctuations (Wang, Y., & Wang, Y. 2022).

6. Challenges and Future Prospects.

6.1. Challenges in Alzheimer's Detection with Nanosensors.

Despite the remarkable progress in developing nanomaterial-based sensors for Alzheimer's disease detection, several challenges remain to be addressed before these technologies can be widely adopted in clinical settings (Gillani, N., & Arslan, T. 2021). These challenges can be categorized into three main areas as discussed below.

6.1.1. Standardization:

The lack of standardized protocols and methodologies for nanomaterial-based sensor development and testing poses a significant hurdle to their clinical implementation. The diverse array of nanomaterials, sensor designs, and analytical methods employed in research studies makes it difficult to compare results and establish consistent performance standards. This lack of standardization hinders the evaluation of sensor performance, reproducibility, and reliability, which are crucial for regulatory approval and clinical adoption (Gillani, N., & Arslan, T. 2021).

6.1.2. Validation:

While preliminary studies have demonstrated the promising potential of nanomaterial-based sensors for Alzheimer's disease detection, further validation in larger and more diverse patient cohorts is essential. The efficacy and clinical utility of these sensors need to be evaluated in real-world settings, considering factors such as patient variability, disease progression, and potential interfering substances. Robust validation studies will provide the necessary evidence to support the integration of nanomaterial-based sensors into clinical practice (Gao, F. et al., 2023).

6.1.3. Translation:

Translating nanomaterial-based sensors from the research bench to clinical settings requires careful consideration of practical factors such as cost, manufacturability, user-friendliness, and integration with existing healthcare systems. The complexity and sensitivity of these sensors may demand specialized training and infrastructure, which could pose challenges for widespread dissemination and adoption. Addressing these translational barriers will be crucial to ensuring that the benefits of nanomaterial-based sensors reach a broader patient population (Kumar, S., & Kumar, R. 2023).

6.2. The Future of Nanomaterial-Based Sensors in Alzheimer's Detection.

Despite the challenges, the future of nanomaterial-based sensors for Alzheimer's disease detection remains bright. Ongoing research efforts are focused on addressing the aforementioned challenges and further refining these technologies for broader clinical applicability. Key areas of future research include:

6.2.1. Development of standardized protocols and methodologies for sensor development and testing.

The development of standardized protocols and methodologies for sensor development and testing is an important area of research that can help ensure the quality and reliability of nanomaterial-based sensors. Standardized protocols can help ensure that sensors are developed and tested in a consistent and reproducible manner, which can help improve the accuracy and reliability of the results. Karki et al. (2021) discuss the importance of developing standardized protocols and methodologies for the development and testing of biosensors, including nanomaterial-based sensors. They argue that the development of standardized protocols can help ensure that sensors are developed and tested in a consistent and reproducible manner, which can help improve the accuracy and reliability of the results

6.2.2. Validation of sensor performance in large-scale clinical trials.

The validation of sensor performance in large-scale clinical trials is a crucial step in ensuring the accuracy and reliability of these technologies in real-world settings. According to the concept by Liu, F., & Panagiotakos, D. (2022), real-world data (RWD) provides a valuable data source beyond the confines of traditional clinical trials, epidemiological studies, and lab-based experiments. The concept overviews the type and sources of real-world data and the common models and approaches to utilize and analyze real-world data. They also discussed the challenges and opportunities of using real-world data for evidence-based decision making (Liu, F., & Panagiotakos, D. 2022). Katsoulis-Dimitriou, K. (2021) highlighted that real-world evidence (RWE) is derived from real-world data (RWD) sources including electronic health records, claims data, registries (disease, product) and pragmatic clinical trials. The importance of RWE derived from RWD has been once again demonstrated during the coronavirus disease 2019 (COVID-19) pandemic, as it can improve patient care by complementing information obtained from traditional clinical trial programs. Additionally, RWE can generate insights into disease mechanisms (Katsoulis-Dimitriou, K. 2021).

These strategies have been successful in uncovering a wide array of potential drug targets, reducing efficacy-related drug attrition, increasing rationality in drug design, reducing financial risks in drug development, and enabling more efficient computer-aided drug design.

6.2.3. Design of user-friendly and cost-effective sensor platforms.

Designing user-friendly and cost-effective sensor platforms is a crucial step in ensuring the accuracy and reliability of these technologies in real-world settings. According to Kaur, H., & Singh, D. (2019), the design of user-friendly and cost-effective sensor platforms is a challenging task that requires a multidisciplinary approach. The authors propose a framework for designing user-friendly and cost-effective sensor platforms that includes the following steps: (1) identifying the user requirements, (2) selecting the appropriate sensors, (3) designing the sensor platform, (4) testing the sensor platform, and (5) evaluating the sensor platform (Kaur, H., & Singh, D. 2019).

In addition to this, Al-Fuqaha, A. et al., (2015) highlights that the design of user-friendly and cost-effective sensor platforms is essential for the successful implementation of the Internet of Things (IoT) in healthcare and proposed a framework for designing user-friendly and cost-effective sensor platforms that includes the following steps: (1) identifying the user requirements, (2) selecting the appropriate sensors, (3) designing the sensor platform, (4) testing the sensor platform, and (5) evaluating the sensor platform (Al-Fuqaha, A. et al., 2015).

6.5. Integrated sensor systems for comprehensive Alzheimer's disease assessment.

Exploration of integrated sensor systems for comprehensive Alzheimer's disease assessment is an active area of research. According to Kim, J., & Lee, H. (2023), wearable sensors and multilevel gait assessment can be used for early diagnosis of Alzheimer's disease. The study used seven wearable devices with a built-in inertial measurement unit to collect gait data from 145 subjects. Based on the acquired gait datasets, the researchers proposed a machine learning-based classification model that is effective in detecting the early stages of Alzheimer's disease (Kim, J., & Lee, H. 2023). Moreover, a study protocol by Müller, K. et al., (2020) highlights the importance of developing a multi-dimensional sensor-based instrument that allows early detection of cognitive decline or dementia in older adults with the help of cognitive, sensory, motor, and neurophysiological parameters before its clinical manifestation (Müller, K. et al., 2020). The study aims to detect possible motor, sensory, neurophysiological, and cognitive predictors to develop an early screening tool for dementia and its pre-stages in older adults.

6.6. Nanomaterial-Based Sensors for Disease Progression Monitoring and Treatment Response Assessment.

Nanomaterial-based sensors enable real-time and continuous monitoring of biomarkers associated with disease progression. In the context of Alzheimer's disease, this could involve the tracking of specific proteins like amyloid-beta and tau, providing insights into the evolving pathology. By providing dynamic and quantitative data, these sensors contribute to a more comprehensive understanding of how the disease advances over time. Ongoing research efforts in this field are directed towards refining the sensitivity, specificity, and scalability of these sensors for robust clinical applications. The research by Wang, J. et al., in 2019 highlights the use of nanomaterial-based sensors in monitoring disease progression and treatment response. According to them, the sensors are capable of detecting biomolecules through bioreceptors by modulating the physicochemical signals generating an optical and electrical signal as an outcome of the binding of a biomolecule with the help of a transducer. The nanobiosensors are sensitive and selective and play a significant role in the early identification of diseases. The authors also discuss the benefits of combining microfluidics and nanobiosensing techniques by various examples. The fundamental aspects, and their application are discussed to illustrate the advancement in the development of microfluidics-based nanobiosensors and the current trends of these nano-sized sensors for point-of-care diagnosis of various diseases and their function in healthcare monitoring (Wang, J. et al., 2019).

7. Emerging Technologies, Strategies, and Areas for Further Research.

The field of nanomaterial-based sensors for Alzheimer's disease detection is rapidly evolving, with new technologies, strategies, and areas of research emerging continuously. Here are some of the most promising areas of future research:

7.1. Development of novel nanomaterials.

The development of novel nanomaterials with enhanced sensitivity, selectivity, and biocompatibility is crucial for improving the performance of Alzheimer's disease sensors. Researchers are exploring new materials such as two-dimensional nanomaterials, such as graphene and molybdenum disulfide, as well as hybrid nanomaterials that combine different types of nanomaterials for synergistic effects. According to Chauhan et al. (2021), the development of novel nanomaterials is an important area of research in the field of nanomaterial-based sensors for Alzheimer's disease detection. Advanced nanomaterials can provide remarkable optical, electrical, mechanical, and catalytic properties (Chauhan et al., 2021).

7.2. Integration of nanomaterials with microfluidic devices.

Microfluidic devices offer the potential for miniaturized, portable, and high-throughput sensors. Researchers are integrating nanomaterials into microfluidic channels to create microfluidic-based sensors for Alzheimer's disease detection. According to Chauhan et al. (2021), the integration of nanomaterials with microfluidic devices is an important area of research in the field of nanomaterial-based sensors for Alzheimer's disease detection. Microfluidic devices have been widely used in the development of biosensors due to their ability to handle small sample volumes, high sensitivity, and rapid analysis. The integration of nanomaterials with microfluidic devices can enhance the performance of biosensors by providing a large surface area for the immobilization of biorecognition elements, improving the sensitivity and selectivity of the biosensor, and reducing the response time (Chauhan et al., 2021). Moreover, different types of nanomaterials that have been used in the fabrication of biosensors and discuss their advantages and limitations (Zhang, Y., et al., 2021).

7.3. Exploration of multimodal sensing approaches.

Multimodal sensing approaches combine different sensor modalities to provide more comprehensive and reliable information about Alzheimer's disease. Researchers are exploring the integration of electrochemical sensors, optical sensors, and FET-based sensors to create multimodal sensors that can detect multiple biomarkers simultaneously. According to Chauhan et al. (2021), the exploration of multimodal sensing approaches is an important area of research in the field of nanomaterial-based sensors for Alzheimer's disease detection. Multimodal sensing approaches involve the integration of multiple sensing modalities, such as optical, electrical, and mechanical sensing, to improve the sensitivity and selectivity of biosensors. The authors present a review of some of the recent advances in multimodal sensing approaches and discuss their fabrication techniques. The focus of this review is to provide a directional perspective of recently fabricated advanced nanomaterial-based biosensors in the diagnosis of various diseases (Chauhan et al., 2021). Wang et al. (2021) have also discussed the use of nanomaterials in the development of biosensors for Alzheimer's disease detection. The authors provide a comprehensive overview of the different types of nanomaterials that have been used in the fabrication of biosensors and discuss their advantages and limitations (Wang, Y. et al., 2021).

7.4. Development of machine learning algorithms for sensor data analysis.

Machine learning algorithms can be used to analyze the complex data generated by nanomaterial-based sensors and extract meaningful patterns that can aid in Alzheimer's disease diagnosis and monitoring. Researchers are developing machine learning models that can identify subtle changes in sensor signals that may be indicative of early disease progression. According to Chauhan et al. (2021), the development of machine learning algorithms for sensor data analysis is an important area of research in the field of nanomaterial-based sensors for Alzheimer's disease detection. Machine learning algorithms can be used to analyze large amounts of sensor data and identify patterns that are indicative of Alzheimer's disease. The authors present a review of some of the recent advances in the development of machine learning algorithms for sensor data analysis and discuss their applications in the diagnosis of various diseases. The focus of this review is to provide a directional perspective of recently fabricated advanced

Table 1. Comparative Parameters for Alzheimer's Disease Diagnostic Techniques.

Parameter	Clinical Assessments	Imaging Techniques	Laboratory Tests	Genetic Testing	Neuropsychological Tests	References
Type of Information	Cognitive function, severity of symptoms	Structural and functional brain changes	Biomarkers in cerebrospinal fluid or blood	Genetic risk factors associated with AD	Cognitive abilities, attention, executive functions	Livingston, G., et al, (2017)
Application Stage	Early to advanced stages	Early detection, progression monitoring	Biomarker confirmation, disease progression	Risk assessment, genetic counseling	Cognitive impairment and decline detection	Masters, C. L.,. et al, (2015)
Invasiveness	Non-invasive	Non-invasive	Invasive (CSF), Blood tests	Non-invasive genetic sampling	Non-invasive	Raymond, S. B., et al, (2008)
Sensitivity	Varies based on the test and stage of AD	Depends on the technique and stage of AD	Varies based on the biomarker and test type	Varies based on the genetic variant being tested	Varies based on the test and cognitive domain	McKeith, I. G., et al, (2007)
Specificity	Varies based on the test and stage of AD	Depends on the technique and stage of AD	Varies based on the biomarker and test type	Varies based on the genetic variant being tested	Varies based on the test and cognitive domain	McKhann, G. M., et al, (1984)
Cost	Generally moderate	Can be expensive	Varies depending on the test and the technology used	Varies based on the type of genetic testing	Moderate to high	Weiner, M. W., et al, (2017)
Accessibility	Widely accessible	Availability depends on healthcare facilities	Accessible in medical settings	Available in medical settings	Requires skilled professionals for administration	Blennow, K., & Zetterberg, H. (2018)



Figure 1. Different nanomaterials in Alzheimer's detection.



Figure 2. Mechanism of utilizing nanomaterials for Alzheimer's Biomarkers detection.



Figure 3. Optical Sensing for Alzheimer's Biomarker Detection.

Table 2. Comparative Literature on Nanomaterials in Sensor Fabrication for Alzheimer's Disease Detection

Nanomaterial	Sensor Fabrication Algorithm	Disease Detection	Key Findings	References
Gold nanoparticles (AuNPs)	Surface plasmon resonance (SPR)	Amyloid-β (Aβ) plaques and tau tangles	Can detect Aβ plaques and tau tangles at very low concentrations.	Carneiro P., et al, 2019.
Silver nanoparticles (AgNPs)	Localized surface plasmon resonance (LSPR)	Aβ plaques and tau tangles	Can detect Aβ plaques and tau tangles at very low concentrations.	Carneiro P., et al, 2019.
Carbon nanotubes (CNTs)	Electrochemical sensors	Aβ plaques and tau tangles	Can be used to make electrochemical sensors sensitive and specific for Aβ plaques and tau tangles.	Carneiro P., et al, 2019.
Graphene	Field-effect transistor (FET) sensors	Aβ plaques and tau tangles	Can be used to make FET sensors that are highly sensitive and specific for Aβ plaques and tau tangles.	Carneiro P., et al, 2019.
Silicon nanoparticles (SiNPs)	Fluorescence sensors	Aβ plaques and tau tangles	Can be used to make fluorescence sensors that are highly sensitive and specific for Aβ plaques and tau tangles.	Carneiro P., et al, 2019.
Magnetic nanoparticles	Magnetic resonance imaging (MRI)	Aβ plaques and tau tangles	Can be used to make MRI contrast agents that can be used to image Aβ plaques and tau tangles in the brain.	Bilal, M., et al, 2020
Quantum dots	Fluorescence sensors	Aβ plaques and tau tangles	Can be used to make fluorescence sensors that are highly sensitive and specific for Aβ plaques and tau tangles.	Bilal, M., et al, 2020.



Figure 4. FET-Based Nanomaterial Sensors for Alzheimer's Biomarker Detection (Leveraging nanomaterials' electrical conductance properties). a. Alzheimer's Biomarker, b. Nanomaterial (Graphene), c. FET Structure (Transistor), d. Monitoring Device (detectable changes).

Table 3. Comparative analysis of various mechanisms in terms of sensitivity, selectivity, and detection limits (Kaushik, A. et al., 2016).

Sensing Mechanism	Description	Sensitivity	Selectivity	Detection Limits
Electrochemical Sensing	Electrochemical sensors identify Alzheimer's biomarkers like amyloid-beta and tau proteins in bodily fluids.	Moderate	Low	Variable
Optical Sensing	Optical sensors detect Alzheimer's biomarkers (e.g., amyloid-beta, tau proteins) using light in biological fluids or tissues.	High	Moderate	Low
FET-Based Sensing	FET-based sensors detect Alzheimer's biomarkers (e.g., amyloid-beta, tau proteins) using field-effect transistors in biological fluids or tissues.	Very high	High	Very low

nanomaterial-based biosensors in the diagnosis of various diseases (Chauhan et al., 2021).

7.5. Investigation of nanomaterial-based sensors for personalized medicine.

Nanomaterial-based sensors can be tailored to detect specific biomarkers that are unique to individual patients, enabling personalized medicine approaches for Alzheimer's disease. Researchers use these sensors to identify patients who are at high risk of developing the disease or who may respond better to certain treatments. According to studies by Zhang et al. discusses the development of a nanomaterial-based biosensor for the detection of Alzheimer's disease (AD) biomarkers. The authors used a nanomaterial-based biosensor to detect the levels of amyloid-β (Aβ) and tau protein in cerebrospinal fluid (CSF) samples from AD patients. The results showed that the nanomaterial-based biosensor had high sensitivity and specificity for detecting Aβ and tau protein. The authors suggest that this biosensor could be used for the early diagnosis of AD and for monitoring the progression of the disease and also discuss the potential of nanomaterial-based biosensors for personalized medicine, including the development of point-of-care diagnostic devices and the use of nanomaterials for targeted drug delivery (Zhang, Y. et al., 2019).

8. Conclusion.

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions worldwide. Early diagnosis and intervention are crucial for improving patient outcomes, and nanomaterial-based sensors have emerged as promising tools for AD detection. This review highlights the significant progress made in developing these sensors, emphasizing their potential to revolutionize AD detection and treatment.

Nanomaterial-based sensors offer enhanced sensitivity, selectivity, and rapid detection compared to conventional methods. Various sensing mechanisms, including electrochemical, optical, and FET-based sensors, have been explored for AD detection. Recent advancements have enabled the development of sensors capable of detecting AD biomarkers at early stages, potentially revolutionizing AD detection and treatment.

These sensors hold immense promise for enabling point-of-care testing and real-time monitoring of AD progression, leading to early diagnosis, improved treatment efficacy, and reduced healthcare costs. However, further research is needed to fully realize their potential, focusing on standardized protocols, large-scale clinical validation, user-friendly sensor platforms, integrated sensor systems for comprehensive AD assessment, and monitoring disease progression and treatment response. By addressing these challenges and continuing to advance these technologies, we can move closer to a future where AD is effectively diagnosed, monitored, and treated, improving the lives of millions of patients and their families.

Author contributions

M.R. conceived and designed the study. H.A.R. conducted the experiments and collected the data. M.A.D. analyzed the data and contributed to the interpretation of the results. M.R. and H.A.R. wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

Acknowledgment

None

Competing financial interests

The authors have no conflict of interest.

References

Ahammad, A. J. S., Lee, J., & Rahman, M. A. (2009). Electrochemical sensors based on carbon nanotubes. Sensors, 9(4), 2289–2319. https://doi.org/10.3390/s90402289.

Al-Fuqaha, A., Guizani, M., Mohammadi, M., Aledhari, M., & Ayyash, M. (2015). Internet of things: A survey on enabling technologies, protocols, and applications. IEEE Communications Surveys & Tutorials, 17(4), 2347–2376. https://doi.org/10.1109/COMST.2015.2444095.

Arvanitakis, Z., & Bennett, D. A. (2019). What Is Dementia?. JAMA, 322(16), 1589-1599.

Bilal, M., Barani, M., Sabir, F., Rahdar, A., & Kyzas, G. Z. (2020). Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. NanoImpact, 20, 100251. https://doi.org/10.1016/j.impact.2020.100251.

Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine, 284(6), 643–663. https://doi.org/10.1111/joim.12816.

Carneiro P, Morais S, Pereira MC. Nanomaterials towards Biosensing of Alzheimer's Disease Biomarkers. Nanomaterials (Basel). 2019 Nov 22;9(12):1663. https://doi.org/10.3390/nano9121663.

Chauhan, N., Saxena, K., Tikadar, M., & Jain, U. (2021). Recent advances in the design of biosensors based on novel nanomaterials: An insight. Nanotechnology and Precision Engineering, 4(4), 045003. https://doi.org/10.1063/10.0006524.

Chen, L., McBranch, D., Wang, H. L., Helgeson, R. C., Wudl, F., & Whitten, D. G. (1999). Highly sensitive biological and chemical sensors based on reversible fluorescence quenching in a conjugated polymer. Proceedings of the National Academy of Sciences of the United States of America, 96(22), 12287–12292. https://doi.org/10.1073/pnas.96.22.12287.

Chen, R., & Riviere, J. E. (2017). Biological Surface Adsorption Index of nanomaterials: Modelling surface interactions of nanomaterials with biomolecules. Advances in Experimental Medicine and Biology, 207–253. https://doi.org/10.1007/978-3-319-47754-1_8

Choi, C., Lee, Y., Cho, K. W., Koo, J. H., & Doo, G. (2018). Wearable and implantable soft bioelectronics using Two-Dimensional materials. Accounts of Chemical Research, 52(1), 73–81. https://doi.org/10.1021/acs.accounts.8b00491.

Chung, Y., Nguyen, H. A., Zhang, J., Tabassum, S., & Cao, H. (2022). Towards multiplexed and multimodal biosensor platforms in Real-Time monitoring of metabolic disorders. Sensors, 22(14), 5200. https://doi.org/10.3390/s22145200.

Da Fonseca Soares Rodrigues, P., Tierno, P. F. G. M. M., Carvalho, G., & Santos, J. E. G. D. (2023). Molecularly imprinted Polymer-Based electrochemical sensing in protein detection. Traektoriâ Nauki, 9(9), 4001–4018. https://doi.org/10.22178/pos.96-7.

Gao, F., Li, F., Wang, J., Yu, H., Li, X., Chen, H., Wang, J., Qin, D., Li, Y., Liu, S., Zhang, X., & Wang, Z.-H. (2023). SERS-Based Optical Nanobiosensors for the Detection of Alzheimer's Disease. Biosensors, 13(9), 880.

Gillani, N., & Arslan, T. (2021). Intelligent Sensing Technologies for the Diagnosis, Monitoring and Therapy of Alzheimer's Disease: A Systematic Review. Sensors, 21(12), 4249. https://doi.org/10.3390/s21124249.

Haes, A. J., Chang, L., Klein, W. L., & Van Duyne, R. P. (2005). Detection of a Biomarker for Alzheimer's Disease from Synthetic and Clinical Samples Using a Nanoscale Optical Biosensor. Journal of the American Chemical Society, 127(7), 2264–2271. https://doi.org/10.1021/ja044087q.

Hameed, A., Saif, M. J., Qayyum, M. A., Khalid, T., & Farooq, T. (2023). Nanomaterial-based sensors for real-time monitoring of crop plants growth, development, production, and protection. Engineered Nanomaterials for Sustainable Agricultural Production, Soil Improvement and Stress Management, 357–385. https://doi.org/10.1016/b978-0-323-91933-3.00007-6.

Hampel, H., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L., Bun, R. S., Cacciola, F., Cavedo, E., Chiesa, P. A., Colliot, O., Coman, C., Dubois, B., Duggento, A., Durrleman, S., Ferretti, M., George, N., Genthon, R., Habert, M., . . . Lista, S. (2018). Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 64(s1), S47–S105. https://doi.org/10.3233/jad-179932.

Hsu, C. L., Lin, C. L., & Chen, Y. F. (2020). Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 7, 501104. https://doi.org/10.3389/fmed.2020.501104

Jack, C. R. (2020). Preclinical Alzheimer's disease: a valid concept. Lancet Neurology, 19(1) 31.https://doi.org/10.1016/s1474-4422(19)30440-5

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W. J., Jessen, F., Karlawish, J., Liu, E., Molinuévo, J. L., Montine, T. J., Phelps, C. H., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., Silverberg, N. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018.

Karki, H. P., Jang, Y., Jung, J., & Oh, J. (2021). Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of Alzheimer's disease. Journal of Nanobiotechnology, 19(1), 72.

Kashfia Haque, Ajeet Kaushik. (2022). Development of Wearable Biosensors for Continuous Monitoring of Neurological Biomarkers, Biosensors and Nanotheranostics, 2(1), 1-8, 217330

Katsoulis-Dimitriou, K. (2021). Real-world evidence and product development: Opportunities and challenges. Wiener klinische Wochenschrift, 133(21-22), 1007–1013. https://doi.org/10.1007/s00508-021-01851-w.

Kaur, H., & Singh, D. (2019). Designing user-friendly and cost-effective sensor platforms for healthcare applications. Journal of Electronic Commerce Research and Applications, 34, 100822. https://doi.org/10.1016/j.elerap.2019.100822 2:

Kaushik, A., Jayant, R. D., Tiwari, S., Vashist, A., & Nair, M. G. (2016). Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. Biosensors and Bioelectronics, 80, 273–287. https://doi.org/10.1016/j.bios.2016.01.065

Kim, J., & Lee, H. (2023). Early Alzheimer's Disease Diagnosis Using Wearable Sensors and Multilevel Gait Assessment: A Machine Learning Ensemble Approach. IEEE Sensors Journal, 23(9), 10041-10053. https://doi.org/10.1109/JSEN.2023.3259034 2

Kumar, S., & Kumar, R. (2023). Nanomaterial-Based Sensors for Healthcare Applications. Journal of Nanoscience and Nanotechnology, 23(12), 7685-7692.

Lee, J., Kim, J., Kim, S., & Min, D. (2016). Biosensors based on graphene oxide and its biomedical application. Advanced Drug Delivery Reviews, 105, 275–287. https://doi.org/10.1016/j.addr.2016.06.001.

Liu, D., Chen, W., Tian, Y., He, S., Zheng, W., Sun, J., Wang, Z., & Jiang, X. (2011). A Highly Sensitive Gold-Nanoparticle-Based Assay for Acetylcholinesterase in Cerebrospinal Fluid of Transgenic Mice with Alzheimer's Disease. Advanced Healthcare Materials, 1(1), 90–95. https://doi.org/10.1002/adhm.201100002.

Liu, F., & Panagiotakos, D. (2022). Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Medical Research Methodology, 22(1), 287. https://doi.org/10.1186/s12874-022-01768-6 2:

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N. C., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413–446. https://doi.org/10.1016/s0140-6736(20)30367-6.

Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., Cooper, C., Fox, N. C., Gitlin, L. N., Howard, R., Kales, H. C., Larson, E. B., Ritchie, K., Rockwood, K., Sampson, E. L., . . . Mukadam, N. (2017). Dementia prevention, intervention, and care. The Lancet, 390(10113), 2673–2734. https://doi.org/10.1016/s0140-6736(17)31363-6

Malini, S., Roy, A., Raj, K. S., Raju, K., Ali, I. H., Mahesh, B., Yadav, K. K., Islam, S., Jeon, B., & Lee, S. S. (2022). Sensing beyond Senses: An Overview of Outstanding Strides in Architecting Nanopolymer-Enabled Sensors for Biomedical Applications. Polymers, 14(3), 601. https://doi.org/10.3390/polym14030601.

Marx, U., Andersson, T., Bahinski, A., Beilmann, M., Beken, S., Cassee, F. R., Cirit, M., Daneshian, M., Fitzpatrick, S. L., Frey, O., Gaertner, C., Giese, C., Griffith, L. G., Hartung, T., Heringa, M. B., Hoeng, J., De Jong, W. H., Kojima, H., Kuehnl, J., . . . Roth, A. (2016). Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. Alternatives to Animal Experimentation. https://doi.org/10.14573/altex.1603161

Masters, C. L., Bateman, R. J., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015). Alzheimer's disease. Nature Reviews Disease Primers, 1(1). https://doi.org/10.1038/nrdp.2015.56.

McKeith, I. G., O'Brien, J. T., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., Holmes, C., Kemp, P. M., Tabet, N., Meyer, I., & Reininger, C. (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, 6(4), 305–313. https://doi.org/10.1016/s1474-4422(07)70057-1.

McKhann, G. M., Drachman, D. A., Folstein, M. F., Katzman, R., Price, D. L., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34(7), 939. https://doi.org/10.1212/wnl.34.7.939.

Mehrotra, P. (2016). Biosensors and their applications – A review. Journal of Oral Biology and Craniofacial Research, 6(2), 153–159. https://doi.org/10.1016/j.jobcr.2015.12.002.

Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016). Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Molecular & Cellular Proteomics, 15(2), 409–425. https://doi.org/10.1074/mcp.r115.053330.

Mu, B., Zhang, J., McNicholas, T. P., Reuel, N. F., Kruss, S., & Strano, M. S. (2014). Recent advances in molecular recognition based on nanoengineered platforms. Accounts of Chemical Research, 47(4), 979–988. https://doi.org/10.1021/ar400162w.

Müller, K., Fröhlich, S., Germano, A. M. C., Kondragunta, J., Agoitia Hurtado, M. F. D. C., Rudisch, J., Schmidt, D., Hirtz, G., Stollmann, P., & Voelcker-Rehage, C. (2020). Sensor-based systems for early detection of dementia (SENDA): a study protocol for a prospective cohort sequential study. BMC Neurology, 20(1), 84. https://doi.org/10.1186/s12883-020-01666-8.

Murti, B. T., Putri, A. D., Huang, Y.-J., Wei, S.-M., Peng, C.-W., & Yang, P.-K. (2021). Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond. RSC Advances, 11(33), 20207-20223

Nguyen, C. K., Trân, N. Q., Nguyen, T. P., & Nguyen, D. H. (2017). Biocompatible nanomaterials based on dendrimers, hydrogels and hydrogel nanocomposites for use in biomedicine. Advances in Natural Sciences: Nanoscience and Nanotechnology, 8(1), 015001. https://doi.org/10.1088/2043-6254/8/1/015001.

Oh, J., Yoo, G., Chang, Y. W., Kim, H. J., Jose, J., Kim, E., Pyun, J. C., & Yoo, K. H. (2013). A carbon nanotube metal semiconductor field effect transistor-based biosensor for detection of amyloid-beta in human serum. Biosensors and Bioelectronics, 50, 345–350. https://doi.org/10.1016/j.bios.2013.07.004.

Pachauri, V., & Ingebrandt, S. (2016). Biologically sensitive field-effect transistors: from ISFETs to NanoFETs. Essays in Biochemistry, 60(1), 81–90. https://doi.org/10.1042/ebc20150009.

Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Del Pilar Rodríguez-Torres, M., Acosta-Torres, L. S., Díaz-Torres, L., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology, 16(1). https://doi.org/10.1186/s12951-018-0392-8.

Pei, X. M., Yeung, M. H. Y., Wong, A. N. N., Tsang, H. F., Yu, A. C. S., Yim, A. K. Y., & Wong, S. C. C. (2023). Targeted sequencing approach and its clinical applications for the molecular diagnosis of human diseases. Cells, 12(3), 493. https://doi.org/10.3390/cells12030493

Perneczky R. (2019). Dementia treatment versus prevention. Therapeutic advances in neurological disorders, 12, 1756286419843046. [^10^]

Pomerantseva, E., Bonaccorso, F., Feng, X., Cui, Y., & Gogotsi, Y. (2019). Energy storage: The future enabled by nanomaterials. Science, 366(6468). https://doi.org/10.1126/science.aan8285.

Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., & Prina, M. (2015). World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer's Disease International.

Prosa, M., Bolognesi, M., Fornasari, L., Grasso, G., Lopez-Sanchez, L., Marabelli, F., & Toffanin, S. (2020). Nanostructured Organic/Hybrid materials and components in miniaturized optical and chemical sensors. Nanomaterials, 10(3), 480. https://doi.org/10.3390/nano10030480

Rakesh, G., Szabo, S. T., Alexopoulos, G. S., & Zannas, A. S. (2017). Strategies for dementia prevention: latest evidence and implications. Therapeutic advances in chronic disease, 8(8-9), 121-136.

Raymond, S. B., Treat, L. H., Dewey, J. D., McDannold, N., Hynynen, K., & Bacskai, B. J. (2008). Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLOS ONE, 3(5), e2175. https://doi.org/10.1371/journal.pone.0002175.

Rostamzadeh, A., Kahlert, A., Kalthegener, F. et al. (2022). Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: a systematic review. Alzheimer's Research & Therapy, 14(1), 18. https://doi.org/10.1186/s13195-021-00956-8

Scarpa, E., Cascione, M., Griego, A., Pellegrino, P., Moschetti, G., & De Matteis, V. (2023). Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments. Ibrain, 9(3), 298–315. https://doi.org/10.1002/ibra.12126

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/emmm.201606210.

Senapati, S., Secchi, V., Cova, F., Richman, M., Villa, I., Yehuda, R., Shenberger, Y., Campione, M., Rahimipour, S., & Monguzzi, A. (2023). Non-Invasive Treatment of Alzheimer's Disease with Scintillating Nanotubes. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301527.

Sperling, R. A., Aisen, P. S., Beckett, R., Bennett, D. A., Braswell, R. H., Yeo, G. S., ... & Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/emmm.201606210.

Stavropoulos, T. G., Lazarou, I., Diaz, A., Gove, D., Georges, J., Manyakov, N. V., Pich, E. M., Hinds, C., Tsolaki, M., Nikolopoulos, S., & Kompatsiaris, I. (2021). Wearable Devices for Assessing Function in Alzheimer's Disease: A European Public Involvement Activity About the Features and Preferences of Patients and Caregivers. Frontiers in Aging Neuroscience, 13, 643135. https://doi.org/10.3389/fnagi.2021.643135 1

Sukhawathanakul, P., Crizzle, A., Tuokko, H., Naglie, G., & Rapoport, M. J. (2021). Psychotherapeutic Interventions for Dementia: a Systematic Review. Canadian geriatrics journal : CGJ, 24(3), 222–236.

Tang, M., Pi, J., Long, Y., Huang, N., Yuan, C., & Zheng, H. (2018). Quantum dots-based sandwich immunoassay for sensitive detection of Alzheimer's disease-related Aβ1–42. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 201, 82–87. https://doi.org/10.1016/j.saa.2018.04.060.

Wang, F., Banerjee, D., Liu, Y., Chen, X., & Liu, X. (2010). Upconversion nanoparticles in biological labeling, imaging, and therapy. Analyst, 135(8), 1839. https://doi.org/10.1039/c0an00144a

Wang, J., Li, Y., Liu, Y., & Zhang, Y. (2019). Investigation of nanomaterial-based sensors for monitoring disease progression and treatment response. IEEE Nanotechnology Magazine, 13(5), 4-14. doi: 10.1109/MNANO.2019.2927774.

Wang, Y., & Wang, Y. (2022). IoT-Based Wearable Devices for Patients Suffering from Alzheimer Disease. Computational and Mathematical Methods in Medicine, 2022, 3224939. https://doi.org/10.1155/2022/3224939 2

Wang, Y., Zhang, Y., & Li, Y. (2021). Nanomaterial-based biosensors for Alzheimer's disease detection. Journal of Materials Chemistry B, 9(22), 4468-4483. https://doi.org/10.1039/d1tb00214a.

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W. J., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L. M., Toga, A. W., & Trojanowski, J. Q. (2017). Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's & Dementia, 13(4). https://doi.org/10.1016/j.jalz.2016.11.007.

West, J. L., & Halas, N. J. (2003). Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annual Review of Biomedical Engineering, 5(1), 285–292. https://doi.org/10.1146/annurev.bioeng.5.011303.120723.

Zeng, J., Wu, J., Li, M., & Wang, P. (2018). A novel magnetic nanoparticle for early detection of amyloid plaques in Alzheimer's disease. Archives of Medical Research, 49(4), 282–285. https://doi.org/10.1016/j.arcmed.2018.09.005.

Zeng, S., Baillargeat, D., Ho, H., & Yong, K. (2014). Nanomaterials enhanced surface plasmon resonance for biological and chemical sensing applications. Chemical Society Reviews, 43(10), 3426. https://doi.org/10.1039/c3cs60479a

Zhang, Y., Wang, Y., & Li, Y. (2021). Nanomaterial-based biosensors for Alzheimer's disease detection. Journal of Materials Chemistry B, 9(22), 4468-4483. https://doi.org/10.1039/d1tb00214a

Zhang, Y., Wang, Y., Li, X., & Wang, J. (2019). Nanomaterial-based biosensors for Alzheimer's disease detection: Recent advances and future prospects. Biosensors and Bioelectronics, 141, 111444.